The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis
| Autor: | Bonnie Vlahos, Sameer Kotak, Jack F. Bukowski, Stefanie Gaylord, Jean Dudler, Ron Pedersen, Theresa Williams, Hasan Tahir, Piotr Wiland, Douglas J. Veale |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Combination therapy Immunology Placebo Gastroenterology Etanercept 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine Immunology and Allergy In patient 030212 general & internal medicine skin and connective tissue diseases 030203 arthritis & rheumatology business.industry medicine.disease Surgery Clinical trial Dose–response relationship Rheumatoid arthritis Methotrexate business medicine.drug |
| Zdroj: | The Journal of Rheumatology. 43:1268-1277 |
| ISSN: | 1499-2752 0315-162X |
| DOI: | 10.3899/jrheum.151179 |
| Popis: | Objective.An analysis of a clinical trial to assess the effects of treatment reduction and withdrawal on patient-reported outcomes (PRO) in patients with early, moderate to severe rheumatoid arthritis (RA) who achieved 28-joint Disease Activity Score (DAS28) low disease activity (LDA) or remission with etanercept (ETN) plus methotrexate (MTX) therapy.Methods.During treatment induction, patients received open-label ETN 50 mg weekly plus MTX for 52 weeks. In the reduced-treatment phase, patients with DAS28-erythrocyte sedimentation rate (ESR) ≤ 3.2 at Week 39 and DAS28-ESR < 2.6 at Week 52 in the open-label phase were randomized to double-blind treatment with ETN 25 mg plus MTX, MTX, or placebo (PBO) for 39 weeks (weeks 0–39). In the third phase, patients who achieved DAS28 remission (DAS28-ESR < 2.6) or LDA (2.6 ≤ DAS28-ESR ≤ 3.2) at Week 39 in the double-blind phase had all treatment withdrawn and were observed for an additional 26 weeks (weeks 39–65).Results.Of the 306 patients enrolled, 193 were randomized in the double-blind phase and 131 participated in the treatment-withdrawal phase. After reduction or withdrawal of ETN 50 mg/MTX, patients reduced to ETN 25 mg/MTX experienced slight, nonsignificant declines in the majority of PRO measures, whereas switching to PBO or MTX alone caused significant declines. Presenteeism and activity impairment scores were significantly better in the ETN reduced-dose group versus MTX monotherapy and PBO at Week 39 (p ≤ 0.05).Conclusion.In patients with early RA who achieved remission while receiving full-dose ETN/MTX, continuing combination therapy at a lower dose did not cause a significant worsening of PRO response, but switching to MTX alone or PBO did.ClinicalTrials.govidentifier:NCT00913458. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|